Immunotherapy has transformed advanced melanoma from one of the deadliest cancers into one where long-term survival is a realistic possibility for many patients. In landmark trials, roughly half of patients receiving combination immunotherapy were alive at five years, a figure that would have been almost unthinkable two decades ago when the prognosis for metastatic melanoma was measured in months, not years. The treatments work by removing the brakes that melanoma puts on your immune system, freeing your own T cells to attack the tumor. But the reality of immunotherapy is more layered than that headline suggests, and what you experience during treatment depends on which drugs you receive, how your body responds, and a growing list of biological factors researchers are still working to understand.
How Checkpoint Inhibitors Remove the Brakes
Your immune system already has the machinery to recognize and kill melanoma cells. The problem is that tumors learn to flip molecular switches that tell attacking T cells to stand down. The most important of these switches involve two proteins: CTLA-4 and PD-1. Each acts at a different stage of the immune response. CTLA-4 dampens T cell activity early, primarily in the lymph nodes where immune responses are first organized, while PD-1 suppresses T cells later, out in the tissues where they would otherwise be doing their work against the tumor.1PubMed Central. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Melanoma cells exploit the PD-1 pathway by displaying a protein called PD-L1 on their surface. When PD-L1 binds to PD-1 on an approaching T cell, it effectively tells that T cell to ignore the cancer. Drugs like pembrolizumab and nivolumab are antibodies that physically block PD-1, preventing that handshake from happening. With the inhibitory signal removed, T cells can recognize and attack the melanoma.2PubMed. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma Ipilimumab works on the other checkpoint, blocking CTLA-4 so that T cells ramp up more aggressively in the first place. The two approaches target complementary stages of the immune response, which is why combining them often works better than using either alone.
Combination Therapy and Long-Term Survival
The most extensive data on immunotherapy outcomes in advanced melanoma come from the CheckMate 067 trial, which compared three approaches: the combination of nivolumab plus ipilimumab, nivolumab alone, and ipilimumab alone. The results, now tracked for over a decade, tell a striking story. At five years, overall survival was about 52% in the combination group and 44% with nivolumab alone, compared to 26% with ipilimumab alone.3PubMed. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Those numbers held up remarkably well over time. After ten years of follow-up, median overall survival with the combination was about 72 months, meaning half the patients on the combination lived beyond six years. With nivolumab alone the median was roughly 37 months, and with ipilimumab alone it was about 20 months. Among patients who received the combination, more than a third were still alive at the ten-year mark, with melanoma-specific survival still not reached at study closeout.4PubMed Central. 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma For a cancer that once carried a median survival of six to nine months without effective treatment, these numbers represent a genuine paradigm shift.
The benefits were broadly consistent regardless of whether the melanoma carried a BRAF mutation. At a minimum follow-up of six and a half years, patients with BRAF-mutant tumors on the combination had a survival rate of 57%, while those with BRAF-wild-type tumors had a rate of 46%.5PubMed Central. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma Both groups did meaningfully better than patients receiving ipilimumab alone.
A broader real-world picture comes from a large analysis of patients with advanced melanoma treated with various immunotherapy regimens. Across all patients, five-year overall survival was about 36%. Among those who achieved a complete response, the outlook was particularly encouraging: two-year survival from the date of complete response was 94%, and three-year survival was 90%.6JAMA Network Open. Long-Term Survival in Patients With Advanced Melanoma In other words, if immunotherapy drives your melanoma into a complete remission, the odds of staying in remission are very good.
Side Effects You Should Actually Expect
Because checkpoint inhibitors work by unleashing the immune system broadly, they cannot confine their effects to the tumor. The same inhibitory receptors that melanoma exploits also serve a normal purpose: preventing your immune system from attacking your own healthy tissues. When those brakes come off, some patients develop what are called immune-related adverse events, which can affect virtually any organ system.7PubMed Central. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
The most common immune-related side effects include:
- Skin reactions: rash, itching, and vitiligo (patchy loss of skin color) are among the earliest and most frequent.
- Colitis: inflammation of the colon causing diarrhea, abdominal pain, and sometimes bloody stool. More common with ipilimumab-containing regimens.
- Thyroid problems: both overactive and underactive thyroid can develop, sometimes requiring lifelong thyroid hormone replacement.
- Liver inflammation: usually detected through routine blood tests before symptoms appear.
- Lung inflammation: pneumonitis can cause cough and shortness of breath and needs prompt treatment.
Combination therapy with nivolumab plus ipilimumab produces more frequent and more severe side effects than either drug alone. In the CheckMate 067 trial, severe side effects occurred in a substantial portion of patients on the combination. Many patients needed to stop the combination early because of toxicity, but here is a counterintuitive finding that has consistently held up: patients who stopped the combination early because of side effects generally still had good long-term outcomes. The immune system, once activated, often continues its antitumor work even after the drugs are discontinued.
The Steroid Dilemma
When immune-related side effects become severe, the standard treatment is corticosteroids, which suppress the overactive immune response. This creates an obvious tension: you are using immunotherapy to rev up the immune system against cancer, and then using steroids to tamp it back down. The concern that steroids might undermine the anticancer benefit has been widespread among oncologists and patients alike.8PubMed Central. Corticosteroids and Cancer Immunotherapy
Recent data suggest the picture is nuanced. An analysis across six clinical trials found that what matters is peak steroid dose, not the total amount given over time. Higher peak doses were linked to worse progression-free and overall survival, while cumulative dose was not.9PubMed. Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials A separate melanoma-specific analysis found a similar pattern: high peak steroid doses were associated with worse outcomes, and adding a second line of immunosuppression on top of steroids appeared to further reduce survival.10PubMed. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
The practical takeaway is that steroids remain the right tool for managing serious immune-related side effects, but oncology teams increasingly try to keep doses as low as effective and taper quickly. It is a balancing act with no perfect answer, and it is one of the reasons that close monitoring during immunotherapy matters so much.
Treating Melanoma Before Surgery
Immunotherapy was first developed for patients with advanced, inoperable melanoma, but its use has expanded substantially. After surgery for high-risk melanoma, up to a year of adjuvant immunotherapy has become standard to reduce the chance of recurrence.11PubMed. Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment More recently, a growing body of evidence favors giving some immunotherapy before surgery as well, a strategy called neoadjuvant therapy.
A randomized trial directly comparing the two approaches found that patients who received pembrolizumab both before and after surgery had significantly better event-free survival than those who received it only after surgery. At two years, event-free survival was 72% in the neoadjuvant-adjuvant group versus 49% in the adjuvant-only group, and importantly, severe side effect rates were similar between the two groups.12PubMed Central. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma The rationale is that giving immunotherapy while the tumor is still in the body exposes the immune system to the full range of tumor proteins, priming a stronger and more diverse antitumor response than starting treatment after the tumor has already been removed.
New Checkpoint Targets Beyond PD-1 and CTLA-4
Researchers have identified additional immune checkpoints that melanoma can exploit. LAG-3 is one of the most clinically advanced. Like PD-1, it is an inhibitory receptor on T cells, and when both LAG-3 and PD-1 are active simultaneously, T cells become deeply exhausted and unable to fight the tumor effectively. A drug called relatlimab blocks LAG-3 and is now approved in combination with nivolumab for previously untreated advanced melanoma.
In the RELATIVITY-047 trial, the combination of relatlimab and nivolumab more than doubled median progression-free survival compared to nivolumab alone: about 10 months versus under 5 months. At twelve months, roughly 48% of patients on the combination had not progressed, compared to 36% on nivolumab alone.13PubMed Central. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma The combination had a more favorable side-effect profile than nivolumab plus ipilimumab, making it an appealing option for patients who might not tolerate the more intense regimen.
Tumor-Infiltrating Lymphocyte Therapy
For patients whose melanoma has progressed through checkpoint inhibitors, options have historically been limited. Tumor-infiltrating lymphocyte therapy, or TIL therapy, offers a different approach. Instead of removing the brakes on existing T cells, it involves surgically removing a piece of the patient’s tumor, growing the immune cells found within it into enormous numbers in a laboratory, and then infusing billions of those tumor-specific T cells back into the patient.
The TIL product lifileucel became the first approved cell therapy for a solid tumor. In a pooled analysis of patients whose melanoma had progressed on prior immunotherapy, about 31% responded to lifileucel, including some complete responses. Among responders, the duration of benefit was prolonged: the median duration of response had not been reached after more than two years of follow-up, and roughly 40% of responses were still ongoing at data cutoff.14Journal for ImmunoTherapy of Cancer. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies Even among patients whose melanoma had never responded to anti-PD-1 therapy at all, the response rate was about 41%.15PubMed Central. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
TIL therapy is not easy to go through. It requires a preparatory chemotherapy regimen that temporarily wipes out the patient’s existing immune system to make room for the infused cells, followed by a hospital stay of roughly two weeks. But for patients who have exhausted checkpoint inhibitor options, it represents a genuinely new mechanism of action with the potential for durable responses.
Oncolytic Virus Therapy
An entirely different strategy uses a modified herpes virus, called talimogene laherparepvec (T-VEC), which is injected directly into melanoma tumors that can be reached through the skin. The virus preferentially infects and kills cancer cells. As those cells burst, they spill their contents into the surrounding tissue, essentially giving the immune system a close-up look at the tumor’s proteins. At the same time, the virus produces a molecule called GM-CSF that attracts immune cells to the area. The result is both a local destruction of the injected tumor and a broader immune response that can sometimes shrink tumors elsewhere in the body.16PubMed Central. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
T-VEC is most useful for melanoma that involves the skin or lymph nodes but has not spread extensively to internal organs. Its side effects are generally milder than systemic checkpoint inhibitors, often limited to flu-like symptoms after injection. It is sometimes combined with checkpoint inhibitors to try to boost the immune response, though the optimal combinations are still being studied.
Personalized mRNA Cancer Vaccines
One of the most closely watched developments in melanoma immunotherapy is the use of personalized mRNA vaccines. These are conceptually related to the mRNA COVID-19 vaccines but designed for a completely different purpose. Each vaccine is custom-built for an individual patient by sequencing the DNA of their surgically removed melanoma, identifying mutations unique to that tumor, and manufacturing an mRNA vaccine encoding those mutated proteins. The idea is to teach the patient’s immune system to recognize and attack any remaining cells carrying those mutations.
In the phase 2b KEYNOTE-942 trial, a personalized mRNA vaccine called mRNA-4157 (now known as intismeran autogene) was given alongside pembrolizumab after surgery for high-risk melanoma. At 18 months, recurrence-free survival was 79% in patients receiving the vaccine-plus-pembrolizumab combination versus 62% with pembrolizumab alone.17PubMed. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942) After five years of follow-up, the benefit held, with the combination continuing to reduce recurrence by about half. A favorable trend in overall survival also emerged, though the trial was not large enough to confirm that statistically.18PubMed. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study A larger phase 3 trial is underway to confirm these results, but the early data are among the first concrete evidence that a personalized cancer vaccine can meaningfully improve outcomes.
Who Responds and Who Doesn’t
Not every melanoma responds to immunotherapy, and researchers have invested heavily in trying to predict who will benefit. Two biomarkers get the most attention. The first is PD-L1 expression: tumors that display more PD-L1 on their surface tend to respond better to PD-1 inhibitors, which makes intuitive sense since those tumors are relying more heavily on the PD-1 pathway to evade the immune system. The second is tumor mutational burden, a measure of how many mutations a tumor carries. Melanomas tend to have high mutational loads because of ultraviolet radiation damage, and tumors with more mutations generate more abnormal proteins that the immune system can potentially recognize. Higher mutational burden has been linked to better responses to checkpoint inhibitors.19PubMed Central. Prognostic Biomarkers in Evolving Melanoma Immunotherapy
Neither biomarker is reliable enough on its own to decide whether someone should receive immunotherapy. Patients with low PD-L1 expression or low mutational burden sometimes respond well, and patients with high levels of both sometimes do not. Additional biomarkers under investigation include levels of certain immune cells within the tumor, levels of the enzyme LDH in the blood, and the presence of organized immune structures within the tumor tissue.20Holistic Integrative Oncology. Advances in predictive biomarkers for melanoma immunotherapy For now, the standard approach is to offer checkpoint immunotherapy to eligible patients with advanced melanoma regardless of biomarker status, since even patients with unfavorable markers have a meaningful chance of benefiting.
When Melanoma Is Not on the Skin
Most melanoma research and most of the dramatic survival improvements have focused on cutaneous melanoma, the kind that arises from sun-exposed skin. But melanoma can also develop in mucous membranes (the mouth, sinuses, genital tract, or anal canal) and in the eye (uveal melanoma). These subtypes have a very different biology, and immunotherapy works far less well for them.
In mucosal melanoma, checkpoint inhibitors produce responses in a small minority of patients. Anti-PD-1 antibodies yielded a response rate of about 20%, while anti-CTLA-4 antibodies achieved only about 4%. For uveal melanoma, the picture is even bleaker: in one analysis, no patients with uveal melanoma responded to immunotherapy at all, compared to a small response rate with chemotherapy.21PubMed Central. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma Uveal melanoma has far fewer mutations than cutaneous melanoma, which likely explains why the immune system has fewer targets to latch onto. Patients with these rarer subtypes should be aware that the headline survival statistics for immunotherapy come largely from cutaneous melanoma and may not apply to their situation.
Melanoma That Spreads to the Brain
Brain metastases have long been one of the most feared complications of advanced melanoma, and they were historically excluded from immunotherapy trials. The CheckMate 204 study specifically tested nivolumab plus ipilimumab in patients with melanoma brain metastases. Among patients whose brain metastases were not causing symptoms, results were encouraging: about 54% had an intracranial response, and a third achieved a complete response in the brain. Three-year overall survival for this group was roughly 72%.22The Lancet Oncology. Long-term outcomes with nivolumab plus ipilimumab in patients with melanoma brain metastases (CheckMate 204)
For patients with symptomatic brain metastases, however, the story was much less hopeful: only about 17% responded. The difference likely reflects the overall burden of disease and the degree of immune suppression in patients with more aggressive brain involvement. Still, the fact that combination immunotherapy can produce durable complete responses inside the brain has changed the treatment landscape for many patients who would previously have had few options beyond radiation.
The Gut Microbiome Connection
One of the more surprising threads in immunotherapy research is the role of gut bacteria. Studies have consistently found that the composition of a patient’s gut microbiome before starting immunotherapy is linked to how well the treatment works. In melanoma patients, a more diverse microbial community was associated with longer time before cancer progressed. Specific bacterial species were associated with better or worse outcomes: for example, Faecalibacterium prausnitzii was linked to better responses, while certain Bacteroides species were linked to worse ones.23PubMed Central. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
This has prompted clinical trials exploring whether manipulating the gut microbiome could improve immunotherapy outcomes. Strategies under investigation include fecal microbiota transplantation from immunotherapy responders, probiotics, and dietary changes.24PubMed Central. Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review Early fecal transplant trials in melanoma have shown some promise, but this work is still in its infancy. What it means practically right now is less clear. The evidence is not strong enough to recommend any specific probiotic or dietary regimen before immunotherapy, but it does suggest that indiscriminate antibiotic use around the time of treatment could theoretically be counterproductive, something worth discussing with your oncology team.
The Financial Side of Treatment
Immunotherapy is expensive, and cost is a genuine concern even for patients with insurance. Checkpoint inhibitors can cost well over $100,000 per year at list price, and TIL therapy and personalized vaccines are even more costly given the laboratory work involved. Beyond drug costs, the monitoring schedule for immunotherapy is intensive, with regular blood tests, scans, and clinic visits, which creates additional expenses in time, travel, and copayments.
Research on the financial burden of melanoma immunotherapy has found that younger patients, those under 65, report significantly higher financial toxicity and more financial difficulties than older patients, likely because older patients are more often covered by Medicare.25PubMed Central. The experience of financial toxicity among advanced melanoma patients treated with immunotherapy If you are facing immunotherapy for melanoma, it is worth having a candid conversation early with your treatment team’s financial counselors or social workers. Many drug manufacturers offer patient assistance programs, and understanding your likely out-of-pocket exposure before treatment starts can help you plan and reduce one source of stress during an already difficult time.